Trial Outcomes & Findings for Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use (NCT NCT05521880)
NCT ID: NCT05521880
Last Updated: 2026-07-24
Results Overview
One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. So cure or completion (no need for further parenteral antimicrobial therapy) or transition to suppressive antimicrobial therapy at 12 weeks could not be assessed, and no statistical analyses were performed.
TERMINATED
PHASE4
1 participants
12 weeks
2026-07-24
Participant Flow
One patient screen failed and one patient opted out of the study after initial visit
One patient screen failed and one patient opted out of the study after initial visit
Participant milestones
| Measure |
Study Arm
One patient screen failed and one patient opted out of the study after initial visit
|
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared
|
|---|---|---|
|
Overall Study
STARTED
|
1
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Baseline characteristics by cohort
| Measure |
Study Arm
n=1 Participants
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared
|
Total
n=1 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
1 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Age, Categorical
>=65 years
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Sex: Female, Male
Female
|
1 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
1 Participants
n=267 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Race (NIH/OMB)
White
|
1 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
1 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
1 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
1 Participants
n=267 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
PRIMARY outcome
Timeframe: 12 weeksPopulation: Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. So cure or completion (no need for further parenteral antimicrobial therapy) or transition to suppressive antimicrobial therapy at 12 weeks could not be assessed, and no statistical analyses were performed.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Frequency of Clinically Assessed Cure, Completion (no Need for Further Parenteral Antimicrobial Therapy) or Transition to Suppressive Antimicrobial Therapy at 12 Weeks
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. Consequently, no participants contributed evaluable data for this outcome measure, and no statistical analyses were performed.
One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. Consequently, no participants contributed evaluable data(Frequency of non-adherence to antimicrobial therapy) for this outcome measure, and no statistical analyses were performed.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Frequency of Non-adherence to Antimicrobial Therapy (Lack of Follow up or Any Subsequent Scheduled Parenteral Antimicrobial Dose Administration)
|
0 participants
|
—
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Frequency of Hospital Readmission at 30 Days Post Discharge and at 90 Days Post Discharge
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Proportion of Patients With Drug Related AE
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Rate of Follow up at Scheduled in Person Medication for Opioid Use Disorder (MOUD) Visit and Frequency of Follow up/no Shows at Follow up Dosing Visits for MOUD at 12 Weeks
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Proportion of Patients With Positive Urine Drug Screen
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Evaluate Effect of Medication for Opioid Use Disorder (MOUD) Follow up on Cure/Completion or Transition to Suppressive Antimicrobial Therapy.
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Rate of Direct Acting Antiviral (DAA) Initiation for Hepatitis C (HCV) in Patients Enrolled and Rate of DAA Completion and SVR for HCV in Patients Enrolled
|
0 participants
|
0 participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Rates of New HIV Infection
|
0 participants
|
0 participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Rates of Occurrence of New Bacterial Infection Related to OUD
|
0 participants
|
0 participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 12 weeksPopulation: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Outcome measures
| Measure |
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
|
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
|
|---|---|---|
|
Rates of High Risk Behavior at Baseline and During and Post Completion of Antimicrobial Therapy and Follow up.
|
0 participants
|
0 participants
|
Adverse Events
Adverse Outcomes for Participants
Study Arm
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder
University of Maryland Baltimore
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place